Advertisement

Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px
Document › Details

Ipsogen S.A.. (5/2/11). "Press Release: Ipsogen to Present a Study on Genomic Grade in Lobular Carcinoma at the 3rd IMPAKT Breast Conference in Brussels, Belgium". Marseille.

Region Region Brussels
  Country Belgium
Organisations Organisation Ipsogen S.A.
  Today Qiagen Marseille S.A.
  Group Qiagen (Group)
  Organisation 2 Affymetrix Inc. (Nasdaq: AFFX)
  Group Thermo Fisher (Group)
Products Product Genomic Grade™
  Product 2 MapQuant™ Genomic Grade test
Person Person Fert, Vincent (HalioDx 201503– CEO + CO-founder before Ipsogen 200708– President + CEO)
     


IPSOGEN (Alternext - FR0010626028 - ALIPS), a cancer "profiler" that develops, manufactures and markets molecular diagnostic tests for leukemia and breast cancer, today announces that a study on Genomic Grade will be presented at the 3rd IMPAKT Breast Cancer Conference, taking place May 5-7, 2011, in Brussels, Belgium. The Genomic Grade test (GG), a multi-gene expression test, improves determination of tumor grade, a key parameter of long term prognosis in breast cancer. Consequently, the Genomic Grade test leads optimisation of treatment decisions for women with early invasive hormone receptor positive breast cancer.

This study, focusing on lobular carcinoma, a category of breast carcinoma in which tumor grading and establishment of long term prognosis are challenging, is based on a collaboration between Institut Jules Bordet, Belgium, Clinique Universitaire Saint Luc, Belgium, Institut Paoli Calmette, France and IPSOGEN. Results of the study show that even in a particularly difficult-to-characterise tumor type the Genomic Grade test significantly improves determination of tumor grade and therefore long term prognosis .

Poster # 33P: " Genomic Grade Index improves tumor grading of invasive lobular breast
carcinoma. "
Presenter: Otto Metzger-Filho, Jules Bordet Institute, Brussels, Belgium
Friday, May 6, 2011, 16:20 - 17:00, selected posters walk, Gold Hall

About Genomic Grade

The value of tumor grade as one of the key drivers for long term prognosis of hormone receptor positive early invasive breast cancer has been widely documented over the last decade and tumor grade is part of all current treatment guidelines and decision algorithms.

However, assessment of tumor grade, measured to date by histology, suffers two limitations: variability of assessment across pathology labs, and presence of an intermediate category, histologic grade 2, which can represent as much as 50% of tumors and has a limited informative power for treatment decision making.

The Genomic Grade test has been developed to address these 2 limitations. Proliferation genes are the main component of the selected gene signature. The added value of Genomic Grade to identify high and low grade tumors, esp. in histologic grade 2 tumors, has been documented on 3 000 cases. Moreover, Genomic Grade is able to separate Luminal A and Luminal B tumors. In 2009, the Genomic Grade test has been integrated to St Gallen international guidelines as an adjunct to histological grading.

Genomic Grade is currently available as MapQuant™, an Affymetrix micro-array based assay. A PCR version is currently under development, that will allow testing of formalin fixed-parafin embeded specimens.


About Invasive Lobular Carcinoma

Invasive lobular carcinoma, which represents approx. 10% of invasive breast carcinoma, is the second most common histologic type after ductal carcinoma. Its management and treatment modalities are similar to those of ductal carcinoma. However, because of the specific abnormalities characteristising lobular carcinoma cells, it is particularly difficult to reliably measure tumor grade with the standard histologic tools. Moreover, up to 80% of lobular carcinoma are classified as histologic grade 2, an intermediate grade category of limited informative value. It is therefore difficult to apply the well-validated treatment decision algorithms -most of them incorporating tumor grade- for this category of breast carcinoma.


About IPSOGEN

IPSOGEN, cancer profiler, develops and markets molecular diagnostic tests that help to map diseases and guide patients and oncologists' decisions along their therapeutic path. With more than 80 tests already used routinely worldwide for the diagnosis, prognosis and follow-up of thousands of patients with leukaemia, IPSOGEN is now targeting breast cancer with the aim of providing currently inaccessible diagnostic information. Strengthened by its scientific, clinical and technological partnerships, and by its multidisciplinary team in France and the USA, IPSOGEN plans to become a world leader in the molecular profiling of cancers, and to continue the development and promotion of best-in-class diagnostic references that have a significant impact on patients, medical professionals and society. The company headquarters are located in Marseilles , France. Ipsogen has a subsidiary, IPSOGEN Inc., in Stamford, CT, USA. For further information, please visit us at: www.ipsogen.com

Contacts

IPSOGEN

Vincent Fert
CEO
Tél : + 33 (0)4 9129 3090
fert@ipsogen.com

Hélène Peyro-Saint-Paul
CMO
Tél : + 33 (0)4 9129 3090
peyro-saint-paul@ipsogen.com

Pascale Boissel
CFO
Tél : + 33 (0)4 9129 3090
pascale.boissel@ipsogen.com

ATCG-Press
Corporate and Product
Information
Marielle Bricman
Tél : + 33 (0)4 9125 0785
ipsogen@atcg-partners.com

NewCap
Financial communication and
Investor relations
Axelle Vuillermet & Pierre Laurent
Tél : + 33 (0)1 44 71 94 93
ipsogen@newcap.fr

   
Record changed: 2017-04-02

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for Qiagen (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px




» top